About: The journey of remdesivir: from Ebola to COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The journey of remdesivir: from Ebola to COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The journey of remdesivir: from Ebola to COVID-19
Source	Medline; PMC
abstract	Countries around the world are currently fighting the coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a betacoronavirus, belonging to the same genus as severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV. Currently, there are no proven antiviral therapies for COVID-19. Numerous clinical trials have been initiated to identify an effective treatment. One leading candidate is remdesivir (GS-5734), a broad-spectrum antiviral that was initially developed for the treatment of Ebola virus (EBOV). Although remdesivir performed well in preclinical studies, it did not meet efficacy endpoints in a randomized trial conducted during an Ebola outbreak. Remdesivir holds promise for treating COVID-19 based on in vitro activity against SARS-CoV-2, uncontrolled clinical reports, and limited data from randomized trials. Overall, current data are insufficient to judge the efficacy of remdesivir for COVID-19, and the results of additional randomized studies are eagerly anticipated. In this narrative review, we provide an overview of Ebola and coronavirus outbreaks. We then summarize preclinical and clinical studies of remdesivir for Ebola and COVID-19.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.7573/dic.2020-4-14
bibo:pmid	32547625
has license	no-cc
sha1sum (hex)	7ff3a4047e3f87e67136496f8f6c201ef61388d6
schema:url	https://doi.org/10.7573/dic.2020-4-14
resource representing a document's title	The journey of remdesivir: from Ebola to COVID-19
has PubMed Central identifier	PMC7250494
has PubMed identifier	32547625
schema:publication	Drugs Context
resource representing a document's body	covid:7ff3a4047e3f87e67136496f8f6c201ef61388d6#body_text
is schema:about of	named entity 'tick-borne encephalitis' named entity 'placebo-controlled trials' named entity 'oxygen support' named entity 'Remdesivir' named entity 'COVID-19 pandemic' named entity 'Remdesivir' named entity 'COVID-19' named entity 'ECMO' named entity 'intravenously' named entity 'remdesivir' named entity 'EBOV' named entity 'remdesivir' named entity 'monoclonal antibody' named entity 'COVID-19 in the United States' named entity 'RNA viruses' named entity 'molecule' named entity 'REGN-EB3' named entity 'penciclovir' named entity 'endemic' named entity 'virus' named entity 'remdesivir' named entity 'chloroquine' named entity 'Rift Valley fever' named entity 'China' named entity 'Paramyxoviridae' named entity 'SARS-CoV-2' named entity 'oxygen saturation' named entity 'peer-reviewed' named entity 'ribavirin' named entity 'remdesivir' named entity 'MERS-CoV' named entity 'remdesivir' named entity 'PubMed' named entity 'Remdesivir' named entity 'viruses' named entity 'open-label' named entity 'asymptomatic carriage' named entity 'constellation' named entity 'adverse events' named entity 'Omsk hemorrhagic fever' named entity 'viral load' named entity 'remdesivir' named entity 'MAb114' named entity 'Filoviridae' named entity 'ZMapp' named entity 'remdesivir' named entity 'statistical power' named entity 'meningoencephalitis' named entity 'EVD' named entity 'EVD' named entity 'bat' named entity 'EBOV' named entity 'antiviral agent' named entity 'peripheral blood mononuclear cells' named entity 'SARS-CoV' named entity 'respiratory rate' named entity '2-10' named entity 'negative-strand' named entity 'virus' named entity 'randomized trials' named entity 'creatinine clearance' named entity 'pregnant women' named entity 'expanded access' named entity 'coronavirus disease 2019' named entity 'REGN-EB3' named entity 'case reports' named entity 'clinical trials' named entity 'placebo' named entity 'COVID-19' named entity 'human immunodeficiency virus' named entity 'vaccines' named entity 'Remdesivir' named entity 'emerging viruses' named entity 'Humans infected' named entity 'Middle East respiratory syndrome coronavirus' named entity 'Remdesivir' named entity 'developed countries' named entity 'Remdesivir' named entity 'West African outbreak' named entity 'remdesivir' named entity 'Lassa' named entity 'aspartate transaminase'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software